文献速递瓣膜外科

颈动脉与股动脉入路经导管主动脉瓣置换术:当前时代结果相当

Carotid versus femoral access for transcatheter aortic valve replacement: comparable results in the current era.
PubMed 文献 · Eur J Cardiothorac Surg · 2021-01-01

该回顾性研究纳入500例连续接受TAVR的患者,比较经颈动脉(TC,n=100)与经股动脉(TF,n=400)入路30天结局。主要终点心血管死亡和脑血管事件无统计学差异,TC-TAVR不增加死亡或卒中风险,建议股动脉解剖禁忌时首选颈动脉入路。

要点

  • TC-TAVR与TF-TAVR的30天死亡、卒中及主要血管并发症无显著差异。
  • TF组永久起搏器植入率更高(14.9% vs 5.6%,P=0.015)。
  • 股动脉解剖禁忌时,TC-TAVR应作为首选替代入路。

核心结论

  • TC-TAVR与TF-TAVR在30天死亡和卒中方面无统计学显著差异,TC-TAVR不增加死亡或卒中风险。

研究设计与样本

  • 法国南特大学医院2018年1月至2020年1月的回顾性研究,纳入500例连续患者,TC-TAVR组100例,TF-TAVR组400例(均经皮闭合)。

主要发现

  • 30天死亡率TC组2% vs TF组1%(P=0.345)。
  • 卒中发生率TC组2% vs TF组2.5%(P=0.999)。
  • 主要血管并发症TC组2% vs TF组4%(P=0.548)。
  • 永久起搏器植入TF组14.9% vs TC组5.6%(P=0.015)。
  • TC组无中重度主动脉瓣反流(0 vs 3.3%,P=0.08)。

关键数值与推荐

  • 多变量分析显示TC-TAVR与30天死亡或卒中的OR为1.32(95%CI 0.42-4.21,P=0.63)。
  • TC组男性比例69% vs TF组50.5%(P=0.001),外周血管疾病比例86% vs 14.8%(P<0.0001)。
  • 平均年龄TC组79.9±8.1岁 vs TF组81.3±6.9岁(P=0.069),EuroSCORE II 3.8±2.6% vs 4.6±6.0%(P=0.443)。

临床怎么用

  • 对于股动脉解剖禁忌的患者,TC-TAVR应作为首选替代入路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The carotid approach for transcatheter aortic valve replacement (TAVR) has been shown to be feasible and safe. The goal of this study was to compare the 30-day outcomes of trans-carotid (TC) and transfemoral (TF) TAVR. METHODS: This retrospective study enrolled 500 consecutive patients treated by TC-TAVR (n = 100) or TF-TAVR (n = 400) with percutaneous closure between January 2018 and January 2020 at the Nantes University Hospital. The primary end-point was the occurrence of cardiovascular death and cerebrovascular events at 30 days. RESULTS: The mean age was 79.9 ± 8.1 in the TC group and 81.3 ± 6.9 (P = 0.069) in the TF group. The TC group had more men (69% vs 50.5%; P = 0.001) and more patients with peripheral vascular disease (86% vs 14.8%; P < 0.0001). Cardiac characteristics were similar between the groups, and the EuroSCORE II was 3.8 ± 2.6% vs 4.6 ± 6.0%, respectively (P = 0.443). The 30-day mortality was 2% in the TC group versus 1% in the TF group (P = 0.345). TC-TAVR was not associated with an increased risk of stroke (2% vs 2.5%; P = 0.999) or major vascular complications (2% vs 4%; P = 0.548). More permanent pacemakers were implanted in the TF group (14.9% vs 5.6%; P = 0.015), and no moderate or severe aortic regurgitation was observed in the TC group (0 vs 3.3%; P = 0.08). TC-TAVR was not associated with an increased risk of mortality or stroke at 30 days (odds ratio 1.32; 95% confidence interval 0.42-4.21; P = 0.63) in the multivariable analysis. CONCLUSIONS: No statistically significant differences between TC-TAVR and TF-TAVR were observed; therefore, TC-TAVR should be the first alternative in patients with anatomical contraindications to the femoral route.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Marie B, David CH, Guimbretière G, et al. Carotid versus femoral access for transcatheter aortic valve replacement: comparable results in the current era. Eur J Cardiothorac Surg. 2021. PMID: 33724380. doi:10.1093/ejcts/ezab109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。